MIP-3α/CCL20, CCR6, and CCR7 expression in LCH skin and bone lesions.

(A-F, I-J) LCH skin lesion. (A) Hematoxylin and eosin. (B) Anti-CD1a. (C) Anti-CCR6. (D) IgG_2B isotype control for anti-CCR6. (E) Anti-CCR7. (F) IgG₁ isotype control for anti-CCR7. (G) Nonspecific inflammatory skin lesion, anti-CCR6 showing keratinocyte staining. (H) Nonspecific inflammatory skin lesion, anti-CCR7 showing scattered cells with LC morphology staining intensely for CCR7 (arrows) as well as keratinocyte staining. (I) LCH lesion (same case as panels A-F), anti-MIP-3α/CCL20 showing staining of keratinocytes as well as infiltrating cells. (J) Buffer control for panel I; inset, anti-MIP3a/CCL20 staining of tonsil showing expression by crypt epithelium. (K) LCH bone lesion, anti-MIP-3α, showing intense staining of macrophages (top) and light staining of infiltrating pathologic LCs (left). (L) LCH bone lesion, anti-MIP-3α, showing staining of osteoblasts. Panels A-J are original magnification × 200; J inset is original magnification × 20; panels K and L are original magnification × 400.